Adalimumab Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The global adalimumab drugs market studied was anticipated to grow with a CAGR of nearly 5.1% during the forecast period. Increasing prevalence of arthritis, growing acceptance of biopharmaceuticals, and presence of well-defined regulatory guidelines in developed economies are among key trends expected to trigger market growth. As per the Global RA Network, arthritis affecting more than 350 million people and became a leading cause of disability which trigger market growth.

Increasing launches of novel biosimilar and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, introduction of AMGEVITA by Amgen in 2018 is likely to fuel revenue growth in Europe. Similarly, ABP 501, a novel Adalimumab biosimilar by Amgen, is awaiting approval by 2020. Recently approved biologics such as Hyrimoz (adalimumab-adaz) by Novartis and ABRILADA (adalimumab-afzb) by Pfizer are poised to have strong market penetration due to presence of favorable reimbursement scenario. 

Growing patient awareness regarding arthritis disorders and influx of new biopharmaceuticals in the global arena are projected to increase the adoption of adalimumab drugs. In 2019, approximately 54 million adults suffered from arthritis in U.S. alone. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth. 

However, side effects associated with this drug such as vomiting, nausea, internal bleeding, anaphylaxis, respiratory tract infections may restrain the growth of the market.

Scope of the Report

As per the scope of the report, Adalimumab, which is a patent product of the Abbott, is a medication used for treatment of ulcerative colitis, psoriatic arthritis and rheumatoid arthritis. It also known as HUMIRA, intended to inject subcutaneously. It can help in preventing condition causing damage to body. Adalimumab drugs market is segmented by disease type and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Rheumatoid Arthritis Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

• Rheumatoid arthritis is expected to dominate the global adalimumab drugs market through the forecast period. This can be attributed to rising prevalence of rheumatoid arthritis which causes different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.
• According to the World Health Organization, more than 23 million people live with rheumatoid arthritis. Thus, the rheumatoid arthritis segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and low price of biosimilar for the target disease are supplementing the growth of the segment. Introduction of new biosimilars such as Hadlima and Adaly in the treatment of rheumatoid arthritis is poised to create a significant shift in prescription patterns.

To understand key trends, Download Sample Report